Dossier Preparation With AI: What Changes and What Does Not Dossier preparation with AI changes three things: who drafts the first version, how reviewers verify each claim, and what happens when a source document updates. The structure of an AMCP dossier, a global value dossier (GVD), or an HTA submission stays the same. The expertise…

HTACG AI Principles in JCA The HTACG AI Principles in JCA are three rules- accountability, transparency and reporting, that the EU HTA Coordination Group adopted on 15 July 2026 for any use of AI in preparing a Joint Clinical Assessment dossier. MadeAi supports them with a human approval gate at every workflow stage, a timestamped…

What Does JCA Scoping to Evidence Synthesis Mean for Dossier Readiness? JCA scoping to evidence synthesis is the chain of work that turns an anticipated EU Joint Clinical Assessment (JCA) scope into a submission-ready evidence base. End-to-end capability means one PI(E)COS (Population, Intervention/Exposure, Comparison, Outcome, Study Design) data model carries scope anticipation, protocol, search, screening,…

What is the Evidence Challenge for JCA? The evidence challenge for JCA (Joint Clinical Assessment) is managing multiple population, intervention/exposure, comparator, outcome, and study design (PI(E)COS) requests and indirect comparisons within a strict 100-day submission timeframe. The EU Health Technology Assessment Regulation has applied since 12 January 2025. While most commentary focuses on the formal…

Why AI-Native Tag Insights in SLR Matter AI-Native Tag Insights in SLR transform how systematic literature reviews (SLRs) move from raw study lists to actionable evidence maps. In traditional workflows, reviewers manually code study characteristics, then struggle to spot cross-study patterns or conflicting findings. AI-native tagging applies structured labels at scale and surfaces those patterns…

Evidence Generation for AMCP Dossiers Evidence generation for AMCP (Academy of Managed Care Pharmacy) dossiers sits at the center of successful U.S. market access. Healthcare decision-makers rely on these dossiers to evaluate clinical value, economic impact, and real-world performance before making formulary and coverage decisions. Yet traditional manual processes struggle to keep pace with expanding…